- Trial phase
- Approved
- Time to market
- Already approved by CDSCO (India) in July 2026; anticipated to become available in India's private market in the first half of 2027.
- Why 3/10
- The next catalyst is the commercial launch of QDENGA in India's private market, anticipated in H1 2027. However, Dr. Reddy's is only the Indian distributor for Takeda's already-approved vaccine, there is no binary regulatory catalyst ahead. The deal terms were not disclosed, and for a ~$11B diversified pharma company, this is a small portfolio addition, not a company-defining event.
Watch for the commercial launch of QDENGA in India's private market in H1 2027, which will be Dr. Reddy's first foray into vaccine distribution. The financial terms were not disclosed, so the revenue contribution is unclear, this is a distribution deal, not a development deal, and is unlikely to be a needle-mover for a ~$11B market cap company. Monitor quarterly results for any disclosed revenue from the partnership.
Price Chart
Executive Summary
QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine developed and manufactured by Takeda Pharmaceutical Co. (NYSE: TAK). It is already approved in multiple global markets including the EU, UK, Brazil, and several Asian countries. Dr. Reddy's Laboratories (NYSE: RDY) entered into an exclusive distribution and marketing agreement with Takeda for QDENGA in India's private market. The vaccine was approved by India's CDSCO in July 2026 and is expected to launch in H1 2027. For Dr. Reddy's, this is a commercial distribution deal for an already-approved product, not a development-stage binary. The financial terms were not disclosed, and for a diversified ~$11B pharmaceutical company, this represents a modest portfolio expansion rather than a company-defining catalyst.
How It Works
QDENGA is a live-attenuated tetravalent dengue vaccine, meaning it contains weakened versions of all four dengue virus serotypes. It trains the immune system to recognize and fight the dengue virus without causing the disease itself. It is given as a two-dose subcutaneous injection three months apart.
Trial Status
QDENGA is already approved in multiple global markets. Takeda completed pivotal Phase 3 trials (TIDES) demonstrating efficacy against all four dengue serotypes. India's CDSCO approved the vaccine in July 2026. Dr. Reddy's will distribute it in India's private market starting H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Commercial launch of QDENGA in India's private market (anticipated H1 2027)
- Potential expansion into India's public immunization programs (speculative, no timeline)
- Quarterly earnings disclosures of any QDENGA-related revenue
Source Filing
The SecBot filing or press-release report that triggered this drug report:
DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report